Nixenca (Duloxetine)

Duloxetine, the active ingredient in Nixenca, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as an oral tablet for oral use. It is prescribed for depressive and anxiety disorders as well as certain chronic pain conditions in adult patients.

GNH USA supplies Nixenca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. Our network ensures timely delivery to meet clinical demand across diverse markets and supports regulatory compliance for each market.

Duloxetine is an SNRI indicated for several psychiatric and pain‑related conditions. - Major depressive disorder: reduces depressive symptoms and improves mood. - Generalized anxiety disorder: alleviates excessive worry and associated physical symptoms. - Diabetic peripheral neuropathic pain: lessens pain intensity and improves functional status. - Fibromyalgia: decreases widespread pain and fatigue. - Chronic musculoskeletal pain: improves pain control and quality of life.

Duloxetine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dry mouth: reduced salivation causing discomfort. - Headache: transient tension‑type headaches. - Insomnia: difficulty initiating or maintaining sleep. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Serotonin syndrome: agitation, hyperthermia, tremor, and autonomic instability. - Severe hypertension: sudden increase in blood pressure. - Suicidal thoughts: emergence of suicidal ideation, particularly early in treatment. - Stevens‑Johnson syndrome: severe skin rash and mucosal involvement. - Bleeding abnormalities: increased risk of gastrointestinal or intracranial bleeding.

Before initiating duloxetine therapy, clinicians should evaluate several safety considerations. - Assess hepatic function: obtain baseline liver enzymes and monitor periodically. - Monitor for suicidal ideation: especially in young adults during the first weeks of treatment. - Avoid abrupt discontinuation: taper the dose to reduce risk of discontinuation syndrome. - Use caution in uncontrolled hypertension: check blood pressure regularly. - Store at room temperature: keep in the original container, protect from moisture and light.

Duloxetine interacts with multiple drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome; discontinue MAOI at least 14 days before starting duloxetine. - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid): heightened serotonin syndrome risk. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase duloxetine plasma levels. - Strong CYP2D6 inhibitors (e.g., paroxetine): may raise duloxetine exposure.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tamoxifen): duloxetine may reduce their efficacy. - Anticoagulants/antiplatelets (e.g., warfarin, NSAIDs): increased bleeding tendency. - Alcohol: may enhance central nervous system depression. - Diuretics: potential for additive hypotensive effect.